Hillstream BioPharma Presentations at 2020 AACR Virtual Annual Meeting II
19 mai 2020 08h00 HE
|
Hillstream BioPharma, Inc.
CHESTER, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (“Hillstream”) today announced that two abstracts highlighting the progress of HSB-1216 (salinomycin QUATRAMER™)...
Hillstream BioPharma Granted Orphan Drug Designation for HSB-1216 (QUATRAMER Salinomycin) for Treatment of Small Cell Lung Cancer (SCLC)
06 janv. 2020 08h00 HE
|
Hillstream BioPharma, Inc.
Positive pre-clinical data with an emerging validated mechanism of action, Ferroptosis HSB-1216 is a novel therapeutic using the QUATRAMER formulation of a potent anti-Ferroptotic compounds,...
Hillstream BioPharma Announces Kwok-Kin Wong, MD, PhD as New Member to Scientific Advisory Board
19 nov. 2019 07h00 HE
|
Hillstream BioPharma, Inc.
CHESTER, N.J., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Hillstream BioPharma Inc. (“Hillstream”) today announced the addition of clinician-scientist Kwok-Kin Wong, MD, PhD to Hillstream’s Scientific...
Hillstream BioPharma Announces Collaboration with Ardena to Support QUATRAMER Manufacturing
04 nov. 2019 09h35 HE
|
Hillstream BioPharma, Inc.
CHESTER, N.J., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (“Hillstream”) today announced a collaboration with Ardena to secure manufacturing feasibility and capacity for...